| Symbol | DSGN |
|---|---|
| Name | DESIGN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 6005 HIDDEN VALLEY ROAD,SUITE 110, CARLSBAD, California, 92011, United States |
| Telephone | +1 858 293-4900 |
| Fax | — |
| — | |
| Website | https://www.designtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001807120 |
| Description | Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Additional info from NASDAQ: |
2026-04-28 20:01
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Read more
2026-04-23 17:08
New Form DEFA14A - Design Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001193125-26-173689 <b>Size:</b> 4 MB
Read more
2026-04-23 17:07
New Form DEF 14A - Design Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001193125-26-173678 <b>Size:</b> 9 MB
Read more
2026-04-23 17:03
New Form ARS - Design Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001193125-26-173640 <b>Size:</b> 4 MB
Read more
2026-04-01 20:17
Shapiro David 🟢 acquired 67.5K shares (2 derivative) of Design Therapeutics, Inc. (DSGN) at $10.64 Transaction Date: Mar 31, 2026 | Filing ID: 000006
Read more
2026-04-01 20:03
(99% Neutral) DESIGN THERAPEUTICS, INC. (DSGN) Announces New Board Appointment
Read more
2026-04-01 17:12
New Form 3 - Design Therapeutics, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001559570-26-000004 <b>Size:</b> 8 KB
Read more
2026-03-11 22:28
New Form SCHEDULE 13D/A - Design Therapeutics, Inc. <b>Filed:</b> 2026-03-11 <b>AccNo:</b> 0001072613-26-000257 <b>Size:</b> 125 KB
Read more
2026-03-09 20:06
(30% Negative) DESIGN THERAPEUTICS, INC. (DSGN) Reports Q1 2026 Financial Results
Read more
2026-03-09 20:01
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07545928 | Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Real… | Na | Palliative Care | Not_Yet_Recruiting | 2026-09-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT07127133 | An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at R… | Na | Mild Cognitive Impairment (MCI) | Not_Yet_Recruiting | 2026-08-01 | 2027-08-31 | ClinicalTrials.gov |
| NCT07379125 | Therapeutic RSK1 Targeting in Myelofibrosis | Phase1 | Myelofibrosis | Not_Yet_Recruiting | 2026-05-31 | 2028-12-31 | ClinicalTrials.gov |
| NCT07221747 | PathToScale: The PERSIST Trial | Na | Oral Pre-exposure Prophylaxis (PrEP) | Recruiting | 2026-02-16 | 2026-11-01 | ClinicalTrials.gov |
| NCT07206121 | Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adj… | Na | Breast Cancer | Recruiting | 2026-02-10 | 2032-02-06 | ClinicalTrials.gov |
| NCT06045988 | Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Al… | Na | Alzheimer Disease | Not_Yet_Recruiting | 2026-02-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT07024693 | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | Phase2 | Fuchs Endothelial Corneal Dystrophy | Recruiting | 2025-07-30 | 2026-12-01 | ClinicalTrials.gov |
| NCT06504667 | To Validate Point Mini User Needs | Na | Amputation; Traumatic, Hand | Withdrawn | 2025-07-29 | 2025-07-29 | ClinicalTrials.gov |
| NCT06501092 | To Assess the Utility of the Point Mini in a Clinical Take-home Study | Na | Amputation; Traumatic, Hand | Recruiting | 2025-06-18 | 2026-07-31 | ClinicalTrials.gov |
| NCT06874010 | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | Phase1 | Friedreich Ataxia | Recruiting | 2025-06-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT06772870 | A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants | Phase1 | Friedreich Ataxia | Not_Yet_Recruiting | 2025-02-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06747624 | A Crossover Clinical Trial Investigating the Effects of Geranylgeraniol (GG) Su… | Na | Wellness | Completed | 2025-01-30 | 2025-09-19 | ClinicalTrials.gov |
| NCT06702332 | Single Ascending Dose Study of MSD-001 in Healthy Participants | Phase1 | Mental Health Disorders | Completed | 2024-11-11 | 2025-07-11 | ClinicalTrials.gov |
| NCT06076928 | Brain Computer Interface (BCI) Integrated Wearable Hand Robotic Glove System fo… | Na | Stroke | Recruiting | 2024-08-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT06363721 | A Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Mar… | Na | Oral Health | Recruiting | 2024-07-10 | 2025-08-01 | ClinicalTrials.gov |
| NCT06408337 | Phase I-IIa, to Evaluate the Safety, Feasibility, and Efficacy of the Use of BI… | Phase1 | Cleft Lip and Palate | Recruiting | 2024-04-17 | 2028-12-17 | ClinicalTrials.gov |
| NCT06296628 | Rehabilitation Device for Hand Mirror Therapy | Na | Stroke | Completed | 2024-04-04 | 2025-04-01 | ClinicalTrials.gov |
| NCT06319105 | PathToScale: An Implementation Evaluation | — | Oral Pre-exposure Prophylaxis (PrEP) | Unknown | 2024-03-26 | 2026-04-01 | ClinicalTrials.gov |
| NCT06124625 | Effects of Rehabilitation Combined With a Maintenance Program Compared to Rehab… | Na | Post-COVID-19 Syndrome | Active_Not_Recruiting | 2024-01-31 | 2025-09-01 | ClinicalTrials.gov |
| NCT05962931 | Clinical Trial With Adipose Tissue Stem Cells on Biological Matrix for the Trea… | Phase1 | Venous Ulcer | Unknown | 2023-07-12 | 2025-07-01 | ClinicalTrials.gov |
| NCT05723822 | Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairmen… | Na | Mild Cognitive Impairment | Completed | 2023-02-16 | 2023-03-31 | ClinicalTrials.gov |
| NCT05934825 | Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Pa… | Phase1 | Hidradenitis Suppurativa | Unknown | 2022-10-26 | 2025-10-26 | ClinicalTrials.gov |
| NCT05582720 | Cardioprotective Properties of Vegan Burger | Na | Cardiometabolic Health | Unknown | 2022-10-01 | 2023-05-01 | ClinicalTrials.gov |
| NCT05573698 | Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Pat… | Phase1 | Friedreich Ataxia | Completed | 2022-09-27 | 2023-08-25 | ClinicalTrials.gov |
| NCT04003779 | Reconfiguring the Patient Room to Increase Patient Stability | Na | Elderly, Frail | Completed | 2022-07-14 | 2024-09-29 | ClinicalTrials.gov |
| NCT05285540 | Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia | Phase1 | Friedreich Ataxia | Completed | 2022-03-11 | 2022-12-19 | ClinicalTrials.gov |
| NCT05048394 | Teleoperation Experimental Comparison With Able-bodied Subjects | Na | Amputation; Traumatic, Arm, Upper | Completed | 2022-03-01 | 2023-07-31 | ClinicalTrials.gov |
| NCT05234658 | Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcino… | Phase2 | Basal Cell Carcinoma | Unknown | 2022-01-21 | 2024-12-01 | ClinicalTrials.gov |
| NCT04740099 | Surviving Opioid Overdose With Naloxone Education and Resuscitation Trial (SOON… | Na | Opioid Use | Withdrawn | 2021-12-01 | 2023-03-01 | ClinicalTrials.gov |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Pati… | — | Sarcoma | Recruiting | 2021-11-19 | 2028-06-30 | ClinicalTrials.gov |
| NCT05025072 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of S… | Phase1 | Healthy Volunteers | Completed | 2021-08-22 | 2021-09-29 | ClinicalTrials.gov |
| NCT04475718 | Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of… | Na | Pregnancy Related | Completed | 2021-05-17 | 2021-12-31 | ClinicalTrials.gov |
| NCT04623281 | Haemodialysis Outcomes & Patient Empowerment Study 02 | — | End Stage Renal Disease | Completed | 2021-01-21 | 2021-06-15 | ClinicalTrials.gov |
| NCT04763278 | Validation of User Needs of the Point Digit With Partial Hand Amputees | Na | Amputation; Traumatic, Hand | Completed | 2021-01-07 | 2022-03-30 | ClinicalTrials.gov |
| NCT05012683 | To Assess the Utility of the Point Partial in a Clinical Take-home Study of Par… | Na | Amputation; Traumatic, Hand | Completed | 2021-01-05 | 2022-12-31 | ClinicalTrials.gov |
| NCT03326115 | Effectiveness of a Peer Visitation Program to Improve Patient Activation and Qu… | Na | Amputation | Unknown | 2020-12-01 | 2021-08-01 | ClinicalTrials.gov |
| NCT04262401 | Promoting Healthy Habits in Metabolic Syndrome | Na | Metabolic Syndrome | Unknown | 2020-11-23 | 2024-12-01 | ClinicalTrials.gov |
| NCT05012657 | Validation of Point Partial User Needs With Partial Finger Amputees | Na | Amputation; Traumatic, Hand | Completed | 2020-11-03 | 2022-12-31 | ClinicalTrials.gov |
| NCT04755790 | To Assess the Utility of the Point Digit in a Clinical Take-home Study | Na | Amputation; Traumatic, Hand | Completed | 2020-05-18 | 2022-12-31 | ClinicalTrials.gov |
| NCT04238533 | Enhanced Auto-Diagnostic Adaptive Precision Trainer for Myoelectric Prosthetic … | Na | Amputation | Unknown | 2020-03-18 | 2021-07-31 | ClinicalTrials.gov |
| NCT04462679 | COMMIT HIV Trial Nepal | Na | Hiv | Unknown | 2020-02-25 | 2021-07-01 | ClinicalTrials.gov |
| NCT04115306 | Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Phase1 | Metastatic Breast Cancer | Recruiting | 2019-11-14 | 2026-10-01 | ClinicalTrials.gov |
| NCT04067622 | Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation,… | Na | Acute Respiratory Failure | Completed | 2019-09-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03478007 | Low-Cost Tool for Compliance and Treatment-Tracking of Low Back Pain Patients | Na | Low Back Pain | Completed | 2019-08-21 | 2021-12-06 | ClinicalTrials.gov |
| NCT03139955 | Bodytrak® Feasibility Study | — | Monitoring, Physiologic | Unknown | 2019-08-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT03858595 | Optimizing Gestational Weight Gain, Birth Weight and Other Perinatal Outcomes A… | Na | Hypertension, Pregnancy-Induced | Unknown | 2019-03-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT03727373 | Qualitative Study for Pain Measurement Using Innovative Health Technology | — | Pain Measurement | Completed | 2018-10-17 | 2018-11-23 | ClinicalTrials.gov |
| NCT03438292 | The Absorption of Bioactive Berberine in Human | Na | Healthy | Completed | 2018-09-25 | 2020-09-11 | ClinicalTrials.gov |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With… | Phase3 | Synovial Sarcoma | Terminated | 2018-09-18 | 2018-11-20 | ClinicalTrials.gov |
| NCT03619382 | An Evaluation Of Healthy Ankle Motion And Morphology | — | Healthy Ankle | Completed | 2018-07-16 | 2020-12-31 | ClinicalTrials.gov |
| NCT04548960 | OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resi… | Na | CANCER | Unknown | 2018-01-06 | 2023-03-31 | ClinicalTrials.gov |
| NCT03381677 | Pedicle Osteotomy for Stenosis Trial | Na | Lumbar Spinal Stenosis | Suspended | 2017-10-26 | 2024-10-26 | ClinicalTrials.gov |
| NCT03253419 | HotShOT: Home Safety Occupational Therapy | Na | Hip Replacement | Withdrawn | 2017-08-15 | 2020-02-28 | ClinicalTrials.gov |
| NCT03171155 | Clinical Study of the Medeon Biodesign XPro™ | Na | Percutaneous Closure of Arteriotomy in Common Femoral Artery | Completed | 2017-05-25 | 2019-09-12 | ClinicalTrials.gov |
| NCT03174522 | The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CL… | Phase3 | Peripheral Arterial Disease (PAD) | Terminated | 2017-04-25 | 2023-02-13 | ClinicalTrials.gov |
| NCT03111238 | The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With… | Phase3 | Peripheral Arterial Disease (PAD) | Terminated | 2017-04-05 | 2021-03-31 | ClinicalTrials.gov |
| NCT03004391 | Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Re… | — | Ovarian Cancer | Completed | 2017-04-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT03072472 | BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnorm… | Na | Colorectal Neoplasms | Completed | 2017-02-14 | 2018-02-13 | ClinicalTrials.gov |
| NCT03169699 | Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data | — | URTI | Unknown | 2017-02-01 | 2018-03-31 | ClinicalTrials.gov |
| NCT02614885 | Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Bre… | — | Prophylactic Mastectomy | Completed | 2016-07-20 | 2017-08-17 | ClinicalTrials.gov |
| NCT02501473 | Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Partic… | Phase1 | Follicular Low Grade Non-Hodgkin's Lymphoma | Terminated | 2016-02-03 | 2019-08-01 | ClinicalTrials.gov |
| NCT02525913 | Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breas… | Na | Breast Cancer | Withdrawn | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02406781 | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced… | Phase2 | Sarcoma | Completed | 2015-06-01 | 2023-01-15 | ClinicalTrials.gov |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezoli… | Phase2 | Sarcoma | Terminated | 2015-04-29 | 2019-02-06 | ClinicalTrials.gov |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase1 | Sarcoma | Terminated | 2015-02-28 | 2019-03-29 | ClinicalTrials.gov |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children Wit… | Phase1 | Acute Lymphoblastic Leukemia (ALL) | Completed | 2015-02-16 | 2024-06-28 | ClinicalTrials.gov |
| NCT02122861 | Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed … | Phase1 | Melanoma - Currently Enrolling | Completed | 2014-05-30 | 2018-12-15 | ClinicalTrials.gov |
| NCT02073773 | Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients … | Phase3 | Ischaemic Stroke | Completed | 2014-01-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metast… | Phase1 | Melanoma | Completed | 2013-11-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01954927 | Pain Management in Children and Young Adults With Sickle Cell Disease | Phase2 | Sickle Cell Disease | Completed | 2013-10-07 | 2018-01-03 | ClinicalTrials.gov |
| NCT01886144 | Effects of Bracing on Knee Osteoarthritis (OA) | — | Knee Osteoarthritis | Completed | 2013-07-01 | — | ClinicalTrials.gov |
| NCT01397604 | The Effects of GLA on Human Volunteers | Phase1 | Healthy Volunteers | Completed | 2011-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00883584 | IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study | Phase2 | Chronic Obstructive Pulmonary Disease | Unknown | 2008-07-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00872326 | Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients … | Phase1 | Peripheral Vascular Diseases | Completed | 2007-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00685555 | Healthy Futures Project: A Community Based Obesity Prevention Program | Early_Phase1 | Overweight | Completed | 2005-10-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00444847 | Effect of Repeated Exposures to Compressed Air on Patients With AIDS | Phase2 | AIDS | Withdrawn | 2005-07-01 | — | ClinicalTrials.gov |
Total clinical trials: 76
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Virtual Reality based therapy | Drug | Phase PHASE3 | Ischaemic Stroke | COMPLETED | NCT02073773 |
| Levodopa | Other | Phase PHASE3 | Ischaemic Stroke | COMPLETED | NCT02073773 |
| Virtual Reality based therapy | Drug | Phase PHASE3 | Ischaemic Stroke | COMPLETED | NCT02073773 |
| Levodopa | Other | Phase PHASE3 | Ischaemic Stroke | COMPLETED | NCT02073773 |
| Placebo | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT01954927 |
| Gabapentin | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT01954927 |
| Placebo | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT01954927 |
| Gabapentin | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT01954927 |
| DT-216 matching Placebo | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05285540 |
| DT-216 | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05285540 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT00883584 |
| IMD-1041 | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT00883584 |
| Placebo | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT00883584 |
| IMD-1041 | Other | Phase PHASE2 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT00883584 |
| Switch active lifestyles from MediaWise | Other | Phase EARLY_PHASE1 | Overweight | COMPLETED | NCT00685555 |
| Switch active lifestyles brought to you by MediaWise | Other | Phase EARLY_PHASE1 | Overweight | COMPLETED | NCT00685555 |
| Squalene | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| GLA-SE | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| GLA-AF | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| Squalene | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| GLA-SE | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| GLA-AF | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| Knee OA Brace | Other | Preclinical | Knee Osteoarthritis | COMPLETED | NCT01886144 |
| Knee OA Brace | Other | Preclinical | Knee Osteoarthritis | COMPLETED | NCT01886144 |
| Autologous Bone Marrow Mononuclear Cells | Other | Phase PHASE1 | Peripheral Vascular Diseases | COMPLETED | NCT00872326 |
| Autologous Bone Marrow Mononuclear Cells | Other | Phase PHASE1 | Peripheral Vascular Diseases | COMPLETED | NCT00872326 |
| RFA Applicator | Other | Approved | Breast Cancer | WITHDRAWN | NCT02525913 |
| RFA Applicator | Other | Approved | Breast Cancer | WITHDRAWN | NCT02525913 |
| Hyperbaric chamber | Other | Phase PHASE2 | AIDS | WITHDRAWN | NCT00444847 |
| Hyperbaric chamber | Other | Phase PHASE2 | AIDS | WITHDRAWN | NCT00444847 |
| IDC-G305 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02015416 |
| IDC-G305 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02015416 |
| RFA | Other | Preclinical | Prophylactic Mastectomy | COMPLETED | NCT02614885 |
| RFA | Other | Preclinical | Prophylactic Mastectomy | COMPLETED | NCT02614885 |
| RFA | Other | Preclinical | Prophylactic Mastectomy | COMPLETED | NCT02614885 |
| Endocuff Vision | Other | Approved | Colorectal Neoplasms | COMPLETED | NCT03072472 |
| Endocuff Vision | Other | Approved | Colorectal Neoplasms | COMPLETED | NCT03072472 |
| ID-LV305 | Other | Phase PHASE1 | Melanoma - Currently Enrolling | COMPLETED | NCT02122861 |
| ID-LV305 | Other | Phase PHASE1 | Melanoma - Currently Enrolling | COMPLETED | NCT02122861 |
| Bodytrak | Other | Preclinical | Monitoring, Physiologic | UNKNOWN | NCT03139955 |
| Bodytrak | Other | Preclinical | Monitoring, Physiologic | UNKNOWN | NCT03139955 |
| Bodytrak | Other | Preclinical | Monitoring, Physiologic | UNKNOWN | NCT03139955 |
| XPro System | Other | Approved | Percutaneous Closure of Arteriotomy in Common Femoral Artery | COMPLETED | NCT03171155 |
| XPro System | Other | Approved | Percutaneous Closure of Arteriotomy in Common Femoral Artery | COMPLETED | NCT03171155 |
| XPro System | Other | Approved | Percutaneous Closure of Arteriotomy in Common Femoral Artery | COMPLETED | NCT03171155 |
| Home for Life mobile application | Other | Approved | Hip Replacement | WITHDRAWN | NCT03253419 |
| Home for Life mobile application | Other | Approved | Hip Replacement | WITHDRAWN | NCT03253419 |
| G305-matching placebo | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| LV305-matching placebo | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| G305 | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| LV305 | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| G305-matching placebo | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| LV305-matching placebo | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| G305 | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| LV305 | Other | Phase PHASE3 | Synovial Sarcoma | TERMINATED | NCT03520959 |
| Metronomic CPA | Other | Phase PHASE1 | Sarcoma | TERMINATED | NCT02387125 |
| G100 | Other | Phase PHASE1 | Sarcoma | TERMINATED | NCT02387125 |
| CMB305 | Other | Phase PHASE1 | Sarcoma | TERMINATED | NCT02387125 |
| Metronomic CPA | Other | Phase PHASE1 | Sarcoma | TERMINATED | NCT02387125 |
| G100 | Other | Phase PHASE1 | Sarcoma | TERMINATED | NCT02387125 |
| CMB305 | Other | Phase PHASE1 | Sarcoma | TERMINATED | NCT02387125 |
| atezolizumab | Other | Phase PHASE2 | Sarcoma | TERMINATED | NCT02609984 |
| CMB305 | Other | Phase PHASE2 | Sarcoma | TERMINATED | NCT02609984 |
| atezolizumab | Other | Phase PHASE2 | Sarcoma | TERMINATED | NCT02609984 |
| CMB305 | Other | Phase PHASE2 | Sarcoma | TERMINATED | NCT02609984 |
| COMMIT mHealth application | Other | Approved | Hiv | UNKNOWN | NCT04462679 |
| COMMIT mHealth application | Other | Approved | Hiv | UNKNOWN | NCT04462679 |
| Control | Other | Approved | Lumbar Spinal Stenosis | SUSPENDED | NCT03381677 |
| Pedicle Lengthening Osteotomy with Altum® Device | Device | Approved | Lumbar Spinal Stenosis | SUSPENDED | NCT03381677 |
| Control | Other | Approved | Lumbar Spinal Stenosis | SUSPENDED | NCT03381677 |
| Pedicle Lengthening Osteotomy with Altum® Device | Device | Approved | Lumbar Spinal Stenosis | SUSPENDED | NCT03381677 |
| Rituximab | Other | Phase PHASE1 | Follicular Low Grade Non-Hodgkin's Lymphoma | TERMINATED | NCT02501473 |
| Pembrolizumab | Other | Phase PHASE1 | Follicular Low Grade Non-Hodgkin's Lymphoma | TERMINATED | NCT02501473 |
| G100 | Other | Phase PHASE1 | Follicular Low Grade Non-Hodgkin's Lymphoma | TERMINATED | NCT02501473 |
| Rituximab | Other | Phase PHASE1 | Follicular Low Grade Non-Hodgkin's Lymphoma | TERMINATED | NCT02501473 |
| Pembrolizumab | Other | Phase PHASE1 | Follicular Low Grade Non-Hodgkin's Lymphoma | TERMINATED | NCT02501473 |
| G100 | Other | Phase PHASE1 | Follicular Low Grade Non-Hodgkin's Lymphoma | TERMINATED | NCT02501473 |
| Peer Visitation Program | Other | Approved | Amputation | UNKNOWN | NCT03326115 |
| Peer Visitation Program | Other | Approved | Amputation | UNKNOWN | NCT03326115 |
| Conventional training | Other | Approved | Amputation | UNKNOWN | NCT04238533 |
| eADAPT training | Other | Approved | Amputation | UNKNOWN | NCT04238533 |
| Conventional training | Other | Approved | Amputation | UNKNOWN | NCT04238533 |
| eADAPT training | Other | Approved | Amputation | UNKNOWN | NCT04238533 |
| Quillaja extract emulsified berberine | Other | Approved | Healthy | COMPLETED | NCT03438292 |
| TPGS emulsified berberine | Other | Approved | Healthy | COMPLETED | NCT03438292 |
| Berberine | Other | Approved | Healthy | COMPLETED | NCT03438292 |
| Quillaja extract emulsified berberine | Other | Approved | Healthy | COMPLETED | NCT03438292 |
| TPGS emulsified berberine | Other | Approved | Healthy | COMPLETED | NCT03438292 |
| Berberine | Other | Approved | Healthy | COMPLETED | NCT03438292 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03111238 |
| REX-001 | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03111238 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03111238 |
| REX-001 | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03111238 |
| Radiographs | Other | Preclinical | Healthy Ankle | COMPLETED | NCT03619382 |
| Cone Beam Computed Tomography | Other | Preclinical | Healthy Ankle | COMPLETED | NCT03619382 |
| Sixty device | Device | Preclinical | End Stage Renal Disease | COMPLETED | NCT04623281 |
| Sixty device | Device | Preclinical | End Stage Renal Disease | COMPLETED | NCT04623281 |
| cancer patients | Other | Approved | CANCER | UNKNOWN | NCT04548960 |
| cancer patients | Other | Approved | CANCER | UNKNOWN | NCT04548960 |
| Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain | Device | Approved | Hypertension, Pregnancy-Induced | UNKNOWN | NCT03858595 |
| Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain | Device | Approved | Hypertension, Pregnancy-Induced | UNKNOWN | NCT03858595 |
| Hydroxycarbamide film-coated tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025072 |
| Hydroxycarbamide dispersible tablets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025072 |
| Hydroxycarbamide film-coated tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025072 |
| Hydroxycarbamide dispersible tablets | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05025072 |
| Exersides | Other | Approved | Acute Respiratory Failure | COMPLETED | NCT04067622 |
| Exersides | Other | Approved | Acute Respiratory Failure | COMPLETED | NCT04067622 |
| Intervention Technology Plus Coaching | Other | Approved | Low Back Pain | COMPLETED | NCT03478007 |
| Intervention Technology | Other | Approved | Low Back Pain | COMPLETED | NCT03478007 |
| Intervention Technology Plus Coaching | Other | Approved | Low Back Pain | COMPLETED | NCT03478007 |
| Intervention Technology | Other | Approved | Low Back Pain | COMPLETED | NCT03478007 |
| Standard of Care | Other | Approved | Opioid Use | WITHDRAWN | NCT04740099 |
| SOONER Video & Kit | Other | Approved | Opioid Use | WITHDRAWN | NCT04740099 |
| Standard of Care | Other | Approved | Opioid Use | WITHDRAWN | NCT04740099 |
| SOONER Video & Kit | Other | Approved | Opioid Use | WITHDRAWN | NCT04740099 |
| Habit-focused health coaching | Other | Approved | Metabolic Syndrome | UNKNOWN | NCT04262401 |
| Standard health coaching | Other | Approved | Metabolic Syndrome | UNKNOWN | NCT04262401 |
| Habit-focused health coaching | Other | Approved | Metabolic Syndrome | UNKNOWN | NCT04262401 |
| Standard health coaching | Other | Approved | Metabolic Syndrome | UNKNOWN | NCT04262401 |
| Fourth Trimester Mobile Tool | Other | Approved | Pregnancy Related | COMPLETED | NCT04475718 |
| Fourth Trimester Mobile Tool | Other | Approved | Pregnancy Related | COMPLETED | NCT04475718 |
| Fourth Trimester Mobile Tool | Other | Approved | Pregnancy Related | COMPLETED | NCT04475718 |
| Vegan burger | Other | Approved | Cardiometabolic Health | UNKNOWN | NCT05582720 |
| Conventional burger | Other | Approved | Cardiometabolic Health | UNKNOWN | NCT05582720 |
| Vegan burger | Other | Approved | Cardiometabolic Health | UNKNOWN | NCT05582720 |
| Conventional burger | Other | Approved | Cardiometabolic Health | UNKNOWN | NCT05582720 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03174522 |
| REX-001 | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03174522 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03174522 |
| REX-001 | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03174522 |
| Placebo | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03174522 |
| REX-001 | Other | Phase PHASE3 | Peripheral Arterial Disease (PAD) | TERMINATED | NCT03174522 |
| Walkasins | Other | Approved | Mild Cognitive Impairment | COMPLETED | NCT05723822 |
| Walkasins | Other | Approved | Mild Cognitive Impairment | COMPLETED | NCT05723822 |
| Walkasins | Other | Approved | Mild Cognitive Impairment | COMPLETED | NCT05723822 |
| Placebo | Other | Phase PHASE1 | Hidradenitis Suppurativa | UNKNOWN | NCT05934825 |
| Injectable suspension of allogeneic adult mesenchymal stem cells | Other | Phase PHASE1 | Hidradenitis Suppurativa | UNKNOWN | NCT05934825 |
| Placebo | Other | Phase PHASE1 | Hidradenitis Suppurativa | UNKNOWN | NCT05934825 |
| Injectable suspension of allogeneic adult mesenchymal stem cells | Other | Phase PHASE1 | Hidradenitis Suppurativa | UNKNOWN | NCT05934825 |
| Standard treatment (Control) | Drug | Phase PHASE1 | Venous Ulcer | UNKNOWN | NCT05962931 |
| Bioengineered Artificial Mesenchimal Sheet (BAMS) | Other | Phase PHASE1 | Venous Ulcer | UNKNOWN | NCT05962931 |
| Standard treatment (Control) | Drug | Phase PHASE1 | Venous Ulcer | UNKNOWN | NCT05962931 |
| Bioengineered Artificial Mesenchimal Sheet (BAMS) | Other | Phase PHASE1 | Venous Ulcer | UNKNOWN | NCT05962931 |
| Standard treatment (Control) | Drug | Phase PHASE1 | Venous Ulcer | UNKNOWN | NCT05962931 |
| Bioengineered Artificial Mesenchimal Sheet (BAMS) | Other | Phase PHASE1 | Venous Ulcer | UNKNOWN | NCT05962931 |
| Skin Autograft | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| PHIT | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| PHITAH | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| Skin Autograft | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| PHIT | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| PHITAH | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| Skin Autograft | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| PHIT | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| PHITAH | Other | Phase PHASE2 | Basal Cell Carcinoma | UNKNOWN | NCT05234658 |
| Point Digit | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT04755790 |
| Point Digit | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT04755790 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05573698 |
| DT-216 | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05573698 |
| Standard intervention: Offer PrEP choice | Other | Preclinical | Oral Pre-exposure Prophylaxis (PrEP) | UNKNOWN | NCT06319105 |
| Standard intervention: Offer PrEP choice | Other | Preclinical | Oral Pre-exposure Prophylaxis (PrEP) | UNKNOWN | NCT06319105 |
| Standard intervention: Offer PrEP choice | Other | Preclinical | Oral Pre-exposure Prophylaxis (PrEP) | UNKNOWN | NCT06319105 |
| implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT). | Other | Phase PHASE1 | Cleft Lip and Palate | RECRUITING | NCT06408337 |
| implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT). | Other | Phase PHASE1 | Cleft Lip and Palate | RECRUITING | NCT06408337 |
| Point Digit | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT04763278 |
| Point Digit | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT04763278 |
| Point Digit | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT04763278 |
| Point Partial | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT05012657 |
| Point Partial | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT05012657 |
| Standard-of-care myoelectric control algorithm | Other | Approved | Amputation; Traumatic, Arm, Upper | COMPLETED | NCT05048394 |
| Semi-autonomous myoelectric control algorithm | Other | Approved | Amputation; Traumatic, Arm, Upper | COMPLETED | NCT05048394 |
| Standard-of-care myoelectric control algorithm | Other | Approved | Amputation; Traumatic, Arm, Upper | COMPLETED | NCT05048394 |
| Semi-autonomous myoelectric control algorithm | Other | Approved | Amputation; Traumatic, Arm, Upper | COMPLETED | NCT05048394 |
| Point Partial | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT05012683 |
| Point Partial | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT05012683 |
| Point Partial | Other | Approved | Amputation; Traumatic, Hand | COMPLETED | NCT05012683 |
| Saline | Other | Phase PHASE1 | Friedreich Ataxia | NOT_YET_RECRUITING | NCT06772870 |
| DT-216P2 | Other | Phase PHASE1 | Friedreich Ataxia | NOT_YET_RECRUITING | NCT06772870 |
| Room configuration | Other | Approved | Elderly, Frail | COMPLETED | NCT04003779 |
| Placebo | Other | Approved | Wellness | ACTIVE_NOT_RECRUITING | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | ACTIVE_NOT_RECRUITING | NCT06747624 |
| Placebo | Other | Approved | Wellness | ACTIVE_NOT_RECRUITING | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | ACTIVE_NOT_RECRUITING | NCT06747624 |
| PerioPull™ | Other | Approved | Oral Health | RECRUITING | NCT06363721 |
| PerioPull™ | Other | Approved | Oral Health | RECRUITING | NCT06363721 |
| DT-216P2 | Other | Phase PHASE1 | Friedreich Ataxia | RECRUITING | NCT06874010 |
| Daunorubicin | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cytarabine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cyclophosphamide | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| 6-Mercaptopurine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate) | Drug | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal (IT) Methotrexate | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| PEG-asparaginase | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Mitoxantrone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Carfilzomib | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Daunorubicin | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cytarabine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cyclophosphamide | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| 6-Mercaptopurine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate) | Drug | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal (IT) Methotrexate | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| PEG-asparaginase | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Mitoxantrone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Carfilzomib | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Daunorubicin | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cytarabine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cyclophosphamide | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| 6-Mercaptopurine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate) | Drug | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal (IT) Methotrexate | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| PEG-asparaginase | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Mitoxantrone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Carfilzomib | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Mirror Therapy | Drug | Approved | Stroke | COMPLETED | NCT06296628 |
| Miraπ | Other | Approved | Stroke | COMPLETED | NCT06296628 |
| Mirror Therapy | Drug | Approved | Stroke | COMPLETED | NCT06296628 |
| Miraπ | Other | Approved | Stroke | COMPLETED | NCT06296628 |
| Point Mini | Other | Approved | Amputation; Traumatic, Hand | RECRUITING | NCT06501092 |
| Point Mini | Other | Approved | Amputation; Traumatic, Hand | RECRUITING | NCT06501092 |
| Rehabilitation without maintenance program | Other | Approved | Post-COVID-19 Syndrome | ACTIVE_NOT_RECRUITING | NCT06124625 |
| Rehabilitation combined to a digital maintenance program | Other | Approved | Post-COVID-19 Syndrome | ACTIVE_NOT_RECRUITING | NCT06124625 |
| Rehabilitation without maintenance program | Other | Approved | Post-COVID-19 Syndrome | ACTIVE_NOT_RECRUITING | NCT06124625 |
| Rehabilitation combined to a digital maintenance program | Other | Approved | Post-COVID-19 Syndrome | ACTIVE_NOT_RECRUITING | NCT06124625 |
| Rehabilitation without maintenance program | Other | Approved | Post-COVID-19 Syndrome | ACTIVE_NOT_RECRUITING | NCT06124625 |
| Rehabilitation combined to a digital maintenance program | Other | Approved | Post-COVID-19 Syndrome | ACTIVE_NOT_RECRUITING | NCT06124625 |
| Standard Treatment of Care | Drug | Approved | Stroke | RECRUITING | NCT06076928 |
| HandyRehab (HR) | Other | Approved | Stroke | RECRUITING | NCT06076928 |
| Brain Computer Interface integrated HandyRehab platform (BCI-HR) | Other | Approved | Stroke | RECRUITING | NCT06076928 |
| Standard Treatment of Care | Drug | Approved | Stroke | RECRUITING | NCT06076928 |
| HandyRehab (HR) | Other | Approved | Stroke | RECRUITING | NCT06076928 |
| Brain Computer Interface integrated HandyRehab platform (BCI-HR) | Other | Approved | Stroke | RECRUITING | NCT06076928 |
| Placebo Comparator | Other | Phase PHASE1 | Mental Health Disorders | COMPLETED | NCT06702332 |
| MSD-001 | Other | Phase PHASE1 | Mental Health Disorders | COMPLETED | NCT06702332 |
| Placebo Comparator | Other | Phase PHASE1 | Mental Health Disorders | COMPLETED | NCT06702332 |
| MSD-001 | Other | Phase PHASE1 | Mental Health Disorders | COMPLETED | NCT06702332 |
| fulvestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT04115306 |
| PMD-026 | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT04115306 |
| fulvestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT04115306 |
| PMD-026 | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT04115306 |
| Radiofrequency ablation Electrosurgical Device | Device | Approved | Breast Cancer | RECRUITING | NCT07206121 |
| Radiofrequency ablation alone | Other | Approved | Breast Cancer | RECRUITING | NCT07206121 |
| Radiofrequency ablation Electrosurgical Device | Device | Approved | Breast Cancer | RECRUITING | NCT07206121 |
| Radiofrequency ablation alone | Other | Approved | Breast Cancer | RECRUITING | NCT07206121 |
| Combination of MK3475 with Metronomic CP and G100 | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT02406781 |
| Combination of MK3475 with Metronomic CP | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT02406781 |
| Combination of MK3475 with Metronomic CP and G100 | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT02406781 |
| Combination of MK3475 with Metronomic CP | Other | Phase PHASE2 | Sarcoma | COMPLETED | NCT02406781 |
| Point Mini | Other | Approved | Amputation; Traumatic, Hand | WITHDRAWN | NCT06504667 |
| Point Mini | Other | Approved | Amputation; Traumatic, Hand | WITHDRAWN | NCT06504667 |
| Point Mini | Other | Approved | Amputation; Traumatic, Hand | WITHDRAWN | NCT06504667 |
| DT-168 | Other | Phase PHASE2 | Fuchs Endothelial Corneal Dystrophy | RECRUITING | NCT07024693 |
| Non-Contact Sleep Quality Monitor System | Other | Approved | Alzheimer Disease | NOT_YET_RECRUITING | NCT06045988 |
| Non-Contact Sleep Quality Monitor System | Other | Approved | Alzheimer Disease | NOT_YET_RECRUITING | NCT06045988 |
| Non-Contact Sleep Quality Monitor System | Other | Approved | Alzheimer Disease | NOT_YET_RECRUITING | NCT06045988 |
| Observational Translational Study | Other | Preclinical | Sarcoma | RECRUITING | NCT07432932 |
| Observational Translational Study | Other | Preclinical | Sarcoma | RECRUITING | NCT07432932 |
| Enhanced continuation support package | Other | Approved | Oral Pre-exposure Prophylaxis (PrEP) | RECRUITING | NCT07221747 |
| Standard of Care (SoC) | Other | Approved | Oral Pre-exposure Prophylaxis (PrEP) | RECRUITING | NCT07221747 |
| Insole and ankle device | Device | Approved | Mild Cognitive Impairment (MCI) | NOT_YET_RECRUITING | NCT07127133 |
| Insole and ankle device | Device | Approved | Mild Cognitive Impairment (MCI) | NOT_YET_RECRUITING | NCT07127133 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Placebo | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| Geranylgeraniol 300 mg | Other | Approved | Wellness | COMPLETED | NCT06747624 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| ZenctuaryVR+ Interactive Virtual Reality | Other | Approved | Palliative Care | NOT_YET_RECRUITING | NCT07545928 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| PMD-026 | Other | Phase PHASE1 | Myelofibrosis | NOT_YET_RECRUITING | NCT07379125 |
| Switch active lifestyles from MediaWise | BEHAVIORAL | Phase EARLY_PHASE1 | Overweight | COMPLETED | NCT00685555 |
| Switch active lifestyles brought to you by MediaWise | BEHAVIORAL | Phase EARLY_PHASE1 | Overweight | COMPLETED | NCT00685555 |
| Squalene | OTHER | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| GLA-SE | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| GLA-AF | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01397604 |
| Radiographs | RADIATION | Preclinical | Healthy Ankle | COMPLETED | NCT03619382 |
| Cone Beam Computed Tomography | RADIATION | Preclinical | Healthy Ankle | COMPLETED | NCT03619382 |
| Vegan burger | BEHAVIORAL | Approved | Cardiometabolic Health | UNKNOWN | NCT05582720 |
| Conventional burger | BEHAVIORAL | Approved | Cardiometabolic Health | UNKNOWN | NCT05582720 |
| Standard intervention: Offer PrEP choice | OTHER | Preclinical | Oral Pre-exposure Prophylaxis (PrEP) | RECRUITING | NCT06319105 |
| Daunorubicin | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cytarabine | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| 6-Mercaptopurine | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate) | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Intrathecal (IT) Methotrexate | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Vincristine | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| PEG-asparaginase | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Mitoxantrone | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Dexamethasone | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Carfilzomib | DRUG | Phase PHASE1 | Acute Lymphoblastic Leukemia (ALL) | COMPLETED | NCT02303821 |
| Combination of MK3475 with Metronomic CP and G100 | DRUG | Phase PHASE2 | Sarcoma | COMPLETED | NCT02406781 |
| Combination of MK3475 with Metronomic CP | DRUG | Phase PHASE2 | Sarcoma | COMPLETED | NCT02406781 |
| Enhanced continuation support package | BEHAVIORAL | Approved | Oral Pre-exposure Prophylaxis (PrEP) | RECRUITING | NCT07221747 |
| Standard of Care (SoC) | BEHAVIORAL | Approved | Oral Pre-exposure Prophylaxis (PrEP) | RECRUITING | NCT07221747 |
| DT-168 | DRUG | Phase PHASE2 | Fuchs Endothelial Corneal Dystrophy | RECRUITING | NCT07024693 |
| Saline | DRUG | Phase PHASE1 | Friedreich Ataxia | NOT_YET_RECRUITING | NCT06772870 |
| DT-216P2 | DRUG | Phase PHASE1 | Friedreich Ataxia | RECRUITING | NCT06874010 |
| Placebo | DRUG | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05573698 |
| DT-216 matching Placebo | DRUG | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05285540 |
| DT-216 | DRUG | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT05573698 |
Total products: 340